Regarding the basic system of current industry concerns, the "Planning" clearly stated that it will ensure that the top 20 manufacturing companies of the major varieties account for more than 80% of the market share.
Relaxation of concentration
"No surprise, the "plan" will be finally released in May and June." At the 65th National Product Trade Fair held recently, Zhong Qian, a researcher at the Chinese Medical Industry Research Institute participating in the formulation of the "Plan", disclosed that.
According to the "Planning", during the "12th Five-Year Plan" period, China's total output value of the medical industry will increase by more than 20% annually, and by 2015 it will reach 3 trillion yuan.
Regarding the industry concentration that was most concerned about earlier, “Planning†has slowed down the standard – setting “In 2015, the top 100 companies with sales revenue accounted for more than 40% of the total industry sales revenueâ€.
"Originally it was said that the top 50 companies have reached the 40% target, but because the industry concentration is too low, this goal has slowed down." said Xiong Xiong, vice president of the China Medical Industry Research Institute.
Data from the Chinese Medical Management Association shows that in 2010, the top 50 international companies had already accounted for 70% of the global market share. In contrast, China’s largest medical group’s annual sales were only 2.2% of Pfizer, the world’s largest manufacturer. , Market share is disparity.
The development of the industry itself is subject to restrictions. The high-density policy adjustments also directly affect the process of market concentration.
"Further policy regulation, especially the trend of price tightening, the market concentration of companies will be slowed down as a whole." Yu Mingde, president of the China Medical Enterprise Management Association, believes that with the further tightening of pricing policies, the overall concentration of the industry Ascension will be affected to varying degrees.
According to the data from the National Bureau of Statistics, from January to December 2010, the national key industrial enterprises operated smoothly, but under the dual pressure of the national price policy and the tender procurement policy, the profitability space is continuously shrinking, and the key enterprises are mainly Although the business revenue is only 1.6 percentage points lower than the overall industry, the profit growth rate is lower than the industry average growth rate of 12.2%, and the overall profitability is still low.
"At this stage, the overall production capacity of the country's 4,800 production companies is overcapacity, 20% to 40% of production capacity is idle, and more than 1,000 small businesses are not even started." Wang Bo, vice president of the China Medical Enterprise Management Association, said.
Industrial Transformation
Underneath the industry as a whole, in the fine-molecule industry, due to the high-tech and high-profit characteristics of the bio-industry, the biomedical industry is generally optimistic about the industry.
In the sub-sectors of the medical industry, the main business income exceeds 100 billion yuan annually, and the top five sub-sectors such as chemical preparations, Zhongcheng, chemical raw materials and bio-biochemical products industries, and medical device industries have realized profits exceeding 10 billion yuan, including bio-biochemicals. In 2010, the main business income of the product industry increased more than average, with the strongest profitability, and the profit margin was 14.5%.
“In the 12th Five-Year Plan period, China may have 20 to 25 originals industrialized, because before it did a lot of investment in technology transfer, 15 of them are likely to be biological and will be put into production in China.†Yu Mingde told reporter.
The reporter learned that with the development of the biomedical industry, internationalization is accelerating, and preparations are sold to mainstream medical markets such as Europe, the United States, and Japan. Companies such as Nantong All Asia, Huahaiye, and Shenzhen East Sunshine will achieve over US$4 billion in exports of pharmaceutical preparations. With the advancement of the new GMP, 100 pharmaceutical companies will become the world's leading market.
"In the period of the 11th Five-Year Plan period, we made a relatively large adjustment, from raw materials to formulations, so the overall growth was relatively slow," said Zhu Kangqin, deputy general manager of Zhejiang Haizheng Industry Co., Ltd. (600267.SH). Under the guidance policy, high value-added formulation business will become the main source of profit for Hisun during the 12th Five-Year Plan period."
“Before we built a company in the United States, we will also start a company in Europe to complete the network layout in the global mainstream market.†Zhu Kangqin said.
At the same time, the "planning" also put forward clear numerical indicators for the current industry focus, ensuring that the top 20 manufacturing companies of the major varieties accounted for more than 80% of the market share.
Induction Hob
Induction Hob,free standing electric range, freestanding electric range,free standing range oven,Induction freestanding gas range
Vast Dragon Trading Limited , https://www.builtinhob.com